sponsored
PatientsVille.com Logo

PatientsVille

Piperacillin Medical Research Studies

Up-to-date List of Piperacillin Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Piperacillin Medical Research Studies

Rank Status Study
1 Recruiting PK/PD of High Dose Pip/Tazo in Obese Patients
Condition: Obesity
Interventions: Drug: Piperacillin/Tazobactam Standard Dose;   Drug: Piperacillin/Tazobactam High Dose
Outcome Measures: Serum maximum concentrations for Piperacillin and tazobactam;   Serum minimum concentrations of Piperacillin and tazobactam;   Number of patients with adverse effects;   Half-life of Piperacillin and tazobactam;   Volume of distribution of both Piperacillin and tazobactam;   Clearance of both Piperacillin and tazobactam;   Area under the curve of both Piperacillin and tazobactam
2 Unknown  Piperacillin-Tazobactam Continuous Versus Intermittent Infusion for Pseudomonas Aeruginosa
Condition: Pseudomonas Aeruginosa Infection
Interventions: Drug: Piperacillin-Tazobactam continuous infusion;   Drug: Piperacillin-Tazobactam intermittent infusion
Outcome Measures: Proportion of patients with satisfactory clinical response (cure or improvement) at the end of Piperacillin-Tazobactam treatment;   Proportion of patients with clinical response (cure or improvement) at 3 days;   Proportion of patients with microbiological response;   Time to defervescence;   Time to clinical cure;   Mortality;   Proportion of patients with adverse effects
3 Recruiting Assessment of the Optimal Dosing of Piperacillin-tazobactam in Intensive Care Unit Patients: Extended Versus Continuous Infusion
Condition: Infectious Disease
Interventions: Drug: Piperacillin continuous infusion;   Drug: Piperacillin extended infusion
Outcome Measures: pharmacokinetics of Piperacillin continuous infusion compared to Piperacillin extended infusion;   95% probability of target attainment (PTA95) versus MIC of different organisms.
4 Recruiting Optimizing Dosing Regimen of Piperacillin/Tazobactam for Nosocomial Pneumonia
Condition: Nosocomial Pneumonia
Interventions: Drug: C Group;   Drug: E Group
Outcome Measures: Extension of the Piperacillin / tazobactam infusion time effect evaluation;   Reducing antibiotic resistance
5 Not yet recruiting Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation
Conditions: Neutropenia;   Hematopoietic Stem Cell Transplantation
Interventions: Drug: Piperacillin;   Drug: Piperacillin-tazobactam combination product
Outcome Measures: febrile rate;   Microbiologic efficacy in febrile patients;   Recovery rate from neutropenia;   AE;   Cost of drug and hospital-stay
6 Unknown  Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses
Condition: Abscess, Intra-Abdominal
Intervention: Drug: Moxifloxacin/Metronidazole or Piperacillin/Tazobactam
Outcome Measures: Clinical success / failure rate at the Test-of-Cure visit;   Clinical + Bacteriological response at End-of-Treatment-visit;   Time to discharge from hospital;   Course of disease on the basis of clinical and laboratory parameters;   safety and tolerability of the study medication;   cost effectiveness of treatment regimes
7 Recruiting Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection
Conditions: Respiratory Tract Infections;   Urinary Tract Infections
Intervention: Drug: Piperacillin Sodium and Sulbactam Sodium
Outcome Measures: The rate of bacterial clearance;   Number of participants with Adverse Events
8 Recruiting Pharmacokinetics of Piperacillin, Given as Continuous Infusion to Patients With Cystic Fibrosis
Condition: Cystic Fibrosis
Intervention: Procedure: Blood test
Outcome Measures: Blood-plasma concentration of Piperacillin;   The time above the minimum inhibitory concentration (T>MIC)
9 Recruiting Antibiotic Safety (SCAMP)
Condition: Complicated Intra Abdominal Infections
Interventions: Drug: ampicillin and metronidazole and gentamicin;   Drug: ampicillin and gentamicin and clindamycin;   Drug: gentamicin and Piperacillin- tazobactam;   Drug: standard of care antibiotics and metronidazole
Outcome Measures: Death;   Number of participants with therapeutic success at Day 30 and Day 90
10 Recruiting A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis
Condition: Cystic Fibrosis
Interventions: Drug: Intermittent, short infusion Ceftazidime;   Drug: Continuous infusion Ceftazidime;   Drug: Intermittent, short infusion Meropenem;   Drug: Continuous infusion Meropenem;   Drug: Intermittent, short infusion Ticarcillin-clavulanate;   Drug: Continuous infusion Ticarcillin-clavulanate;   Drug: Intermittent, short infusion Cefepime;   Drug: Continuous infusion Cefepime;   Drug: Continuous infusion Piperacillin tazobactam;   Drug: Intermittent, short infusion Piperacillin tazobactam
Outcome Measures: Cystic Fibrosis Questionnaire-Revised respiratory component (CFQ-R) respiratory symptom score;   Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory symptom score;   Lung function testing; Forced volume expired in one second (FEV1);   C-reactive peptide (CRP);   Quantitative bacterial load in sputum (total + Pseudomonas aeruginosa);   Time above minimum inhibitory concentration (MIC);   Antibiotic stability;   Pseudomonas aeruginosa virulence gene determinants
11 Unknown  Antibiotic Treatment in Ventilator Associated Tracheobronchitis (VAT)
Condition: Tracheobronchitis
Intervention: Drug: Piperacillin/Tazobactam for 7 days
Outcome Measures: Rate of development of new pneumonia;   ICU length of stay (LOS) and mortality
12 Recruiting Initial Antibiotics and Delayed Appendectomy for Acute Appendicitis
Condition: Acute Appendicitis
Intervention: Drug: Piperacillin + Amoxicillin
Outcome Measures: Number of treatment failures;   Cost-saving of initial nonoperative treatment for early appendicitis
13 Not yet recruiting Patients Response to Early Switch To Oral:Osteomyelitis Study
Condition: Osteomyelitis
Interventions: Drug: oral antibiotics;   Procedure: intravenous antibiotics
Outcome Measures: Clinical Failures;   Evaluation of adverse events related to the use of antibiotics;   Cost of care from the hospital perspective
14 Recruiting Role of Antibiotics in Preventing Infection in Babies Born Through Meconium Stained Liquor
Condition: Neonatal Sepsis
Intervention: Drug: Piperacillin-Tazobactam and Amikacin
Outcome Measures: Incidence of sepsis;   Mortality;;   Respiratory support;;   Duration of Hospital stay;   Complications
15 Not yet recruiting Posaconazole as Salvage Therapy for Aspergillus Pulmonary Infection.
Condition: Clinical Infection
Intervention: Drug: Posaconazole
Outcome Measures: clinical response;   serum galactomannan level
16 Recruiting Drug Monitoring of Antibiotics in Critical Care Patients
Conditions: ARDS;   Sepsis
Intervention:
Outcome Measures: Variability of antibiotic serum concentrations in critically ill patients;   correlate these serum concentrations with clinical and laboratory outcome Correlate serum concentrations with clinical and laboratory outcome parameters
17 Recruiting Study of the Impact of the Minimum Inhibitory Concentration and Susceptible Cut-off Points (CLSI, EUCAST, and Pharmacokinetics/Pharmacodynamics)in Prognosis of Bacteremia by Enterobacteriaceae
Condition: Bacteremia by Enterobacteriaceae
Intervention: Other: Microbiological studies
Outcome Measures: Correlation between the MIC of different antibiotics and the prognosis in patients with bacteremia.;   Correlation between CLSI and EUCAST cut-off points, FC/FD cut-off points with clinical prognosis and of the microbiological response in patients with bacteremia.;   Correlation between Piperacillin/tazobactam serum concentrations and clinical prognosis
18 Unknown  Effect of Antibiotic Rotation in the ICU on the Prevalence of Antibiotic Resistant Gram-negative Colonisation
Condition: Infections
Intervention: Other: Antibiotic rotation
Outcome Measures: Mean prevalence of ICU patients colonised with antimicrobial resistant Gram-negative pathogens;   AMRB acquisition incidence, measured as status conversion from noncolonized to colonized during admission at ICU per 100 patients.;   ICU-acquired bacteraemia rate with AMRB (expressed as the rate of ICU-acquired bacteraemia per 1000 patient-days);   Overall length of ICU-stay hospital-stay and percentage of in-hospital mortality of the total admitted ICU-population.;   Effectiveness of empirical treatment of ICU-acquired bacteraemia, expressed as proportion of bacteraemia for which appropriate antibiotics are administered within 24 hours with antibiotics that the specific pathogens is susceptible for.
19 Recruiting A Comparative Study of ID Fellow-based VS. Pharmacist-based Antibiotic Pre-authorization
Conditions: All Hospitalzied Patients;   No Specific Conditions Requires
Interventions: Procedure: ID fellow-based antibiotic pre-authorization;   Procedure: Pharmacist-based antibiotic pre-authorization
Outcome Measures: Defined Daily Dose (DDD) of antibiotics;   Total duration of antibiotic use
20 Recruiting Neonatal and Paediatric Pharmacokinetics of Antimicrobials Study
Condition: Paediatric Antimicrobial Pharmacokinetics
Intervention:
Outcome Measure: The pharmacokinetic parameters of drug clearance and volume of distribution for each penicillin.

These studies may lead to new treatments and are adding insight into Piperacillin etiology and treatment.

A major focus of Piperacillin research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Piperacillin